Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.36 |
| ▸ | WHR1 | P49842 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18087093 | 0.82 | ALDH1A1 (0.46) | ALDH1A1HRH3CYP2D6PARP1MAPT | |
| SCHEMBL16158913 | 0.81 | ALDH1A1 (0.45) | ALDH1A1HRH3CYP2D6PARP1MAPT | |
| SCHEMBL12537397 | 0.81 | ALDH1A1 (0.45) | ALDH1A1HRH3CYP2D6PARP1MAPT | |
| SCHEMBL2106067 | 0.81 | ALDH1A1 (0.53) | ALDH1A1HRH3CYP2D6PARP1MAPT | |
| Hydrochloric Acid SCHEMBL9956472 | 0.79 | ALDH1A1 (0.44) | ALDH1A1HRH3CYP2D6PARP1MAPT | |
| SCHEMBL16904624 | 0.79 | ALDH1A1 (0.44) | ALDH1A1HRH3CYP2D6PARP1MAPT | |
| SCHEMBL2948497 | 0.74 | ALDH1A1 (0.58) | ALDH1A1HRH3CYP2D6PARP1MAPT | |
| SCHEMBL12026487 | 0.74 | ALDH1A1 (0.54) | ALDH1A1HRH3CYP2D6PARP1MAPT | |
| SCHEMBL12530176 | 0.74 | ALDH1A1 (0.46) | ALDH1A1HRH3CYP2D6PARP1MAPT | |
| SCHEMBL13300924 | 0.74 | ALDH1A1 (0.50) | ALDH1A1HRH3CYP2D6PARP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911403-B2 | Antisense-induced exon exclusion in type VII collagen | SAREPTA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11911403-B2 | Antisense-induced exon exclusion in type VII collagen | COL2A1, COL14A1, COL1A1 | ALDH1A1 4425/4885HRH3 4497/4885CYP2D6 3462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.